SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3D illustration of hair root growing from skin cells, symbolizing strength, growth, and nourishment. Perfect for haircare, cosmetic advertising, medical research, and healthcare concepts.
Funding
Veradermics Gets $150M Series C To Advance Hair Regrowth Pill
Veradermics is the second hair regrowth specialist to fundraise this week, after Pelage Pharmaceuticals announced Wednesday it had brought in $120 million for its own therapy.
October 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Job Trends
Report: U.S. Life Sciences Job Market Report Q3 2025
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
October 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Illustration showing three businesspeople hanging on the edge of a cliff
Layoffs
Q3 Layoffs Up 280% YOY With CSL, Merck, Novo’s Restructurings
Due largely to CSL, Merck and Novo Nordisk’s reorganizations that could total about 19,350 people, Q3 cuts rose significantly year over year and quarter over quarter, based on BioSpace tallies.
October 16, 2025
 · 
4 min read
 · 
Angela Gabriel
IN PARTNERSHIP WITH TRILINK BIOTECHNOLOGIES
Webinar: Design, Build, and Encapsulate: Transforming Digital Sequences into High-Quality, Ready-to-Test mRNA
This webinar, tailored for scientists in academia, biotech, and pharma, explores how intelligent mRNA designs can reduce experimental workloads and improve mRNA performance and efficacy.
October 15, 2025
 · 
1 min read
 · 
BioSpace Insights
Facade of Novo Nordisk's office in Fremont, California
Rare diseases
Novo Offers up to $2.1B for Omeros’ Complement Drug To Expand Rare Disease Work
Novo Nordisk strikes another deal, this time with Omeros, amid a broader pipeline restructuring that recently claimed its cell therapy work.
October 15, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Check mate. hand of businessman moving chess figure Trendy 3d collage in magazine style. Contemporary art. Modern design
GLP-1
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial
After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.
October 15, 2025
 · 
2 min read
 · 
Annalee Armstrong
Group of paper boat in one direction and with one individual pointing in the different way. Business for innovative solution concept.3D rendering on blue background.
Gene therapy
Sarepta’s Not Done With Gene Therapy Yet as LGMD Asset Yields Promising Data
Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene therapy: its limb-girdle muscular dystrophy candidate. But the treatment’s path forward, analysts say, is highly uncertain.
October 15, 2025
 · 
6 min read
 · 
Tristan Manalac
Hair care treatment and repair, follicles with damaged structure and split ends, healthy on beige background 3d render icon set. Cosmetic product with keratin, shampoo mockup banner, 3D illustration
Funding
Pelage Pharmaceuticals Raises $120 Million To Grow Hair Loss Program
The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth.
October 15, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Reaching an agreement. Businessmen shake hands and make a deal. vector
Collaboration
Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal
2025 has been a busy year for Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s AimedBio for an antibody-drug conjugate therapy for cancer.
October 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS